Page last updated: 2024-12-10

mesoranil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID3032472
CHEMBL ID3185330
CHEBI ID82221
SCHEMBL ID24052568
MeSH IDM0059434

Synonyms (45)

Synonym
s-triazine, 2-azido-4-(isopropylamino)-6-(methylthio)-
1,3,5-triazin-2-amine, 4-azido-n-(1-methylethyl)-6-(methylthio)-
NCGC00160368-01
caswell no. 063b
azirpotryne
c 7019
2-azido-4-isopropylamino-6-methylthio-1,3,5-triazine
mezuron
epa pesticide chemical code 263301
einecs 225-101-9
aziprotryne
brasoran
2-azido-4-isopropylamino-6-methylthio-s-triazine
azeprotyrne
brassoron
ciba c 7019
mesoranil
aziprotryne [bsi:iso]
isopropylamino-4-azido-6-methylthio-1,3,5-triazin [german]
aziprotryn
mezaronil
4-azido-n-isopropyl-6-methylthio-1,3,5-triazin-2-ylamine
4-azido-n-(1-methylethyl)-6-(methylthio)-1,3,5-triazin-2-amine
4-azido-6-methylsulfanyl-n-propan-2-yl-1,3,5-triazin-2-amine
NCGC00160368-02
4658-28-0
C19099
fb6h0knm39 ,
isopropylamino-4-azido-6-methylthio-1,3,5-triazin
unii-fb6h0knm39
NCGC00254906-01
cas-4658-28-0
dtxsid3041615 ,
dtxcid1021615
tox21_301004
aziprotryne [iso]
4-azido-n-isopropyl-6-methylthio-1,3,5-triazin-2-amine
CHEBI:82221 ,
AFIIBUOYKYSPKB-UHFFFAOYSA-N
brasoran 50 wp (salt/mix)
CHEMBL3185330
aziprotryne, pestanal(r), analytical standard
4-azido-6-(methylsulfanyl)-n-(propan-2-yl)-1,3,5-triazin-2-amine
Q22712733
SCHEMBL24052568
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,3,5-triazinesAny compound with a 1,3,5-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 3 and 5 of the core benzene ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency3.91520.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency32.34260.000221.22318,912.5098AID1259243; AID1259247; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.52740.001022.650876.6163AID1224838; AID1224839; AID1224893
pregnane X nuclear receptorHomo sapiens (human)Potency61.13060.005428.02631,258.9301AID1346982
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency21.87240.001019.414170.9645AID743191
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency30.63790.000323.4451159.6830AID743066
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency32.50710.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]